ZyVersa Therapeutics, Inc. (ZVSA)
OTCMKTS · Delayed Price · Currency is USD
0.10325
-0.00675 (-6.14%)
At close: Aug 21, 2026
ZyVersa Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.3 | 0.1 | 1.53 | 3.14 | 5.9 | 0.33 |
Cash & Short-Term Investments | 0.3 | 0.1 | 1.53 | 3.14 | 5.9 | 0.33 |
Cash Growth | -81.22% | -93.35% | -51.21% | -46.84% | 1696.27% | 88.11% |
Prepaid Expenses | 0.44 | 0.23 | 0.18 | 0.22 | 0.23 | 0.11 |
Other Current Assets | - | 0.01 | - | - | 0.24 | 0.38 |
Total Current Assets | 0.74 | 0.35 | 1.72 | 3.35 | 6.36 | 0.81 |
Property, Plant & Equipment | - | - | - | 0.01 | 0.12 | 0.03 |
Goodwill | - | - | - | - | 11.9 | - |
Other Intangible Assets | - | - | 18.65 | 18.65 | 100.09 | - |
Long-Term Deferred Charges | - | - | 0.06 | - | - | - |
Other Long-Term Assets | - | - | 0.18 | 0.1 | 0.05 | 0.29 |
Total Assets | 0.74 | 0.35 | 20.6 | 22.11 | 118.51 | 1.13 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 10.24 | 10.12 | 9.34 | 8.43 | 6.03 | 2 |
Accrued Expenses | 3.21 | 2.55 | 1.89 | 1.25 | 0.8 | 0.75 |
Current Portion of Long-Term Debt | - | - | - | - | - | 9.15 |
Current Portion of Leases | - | - | - | 0.01 | 0.11 | - |
Current Income Taxes Payable | - | - | - | - | 0.11 | - |
Other Current Liabilities | 0.22 | 0.06 | 0.01 | 0.51 | 1.15 | 1.73 |
Total Current Liabilities | 14.87 | 12.73 | 11.23 | 10.19 | 8.19 | 13.63 |
Long-Term Deferred Tax Liabilities | - | - | 0.85 | 0.84 | 10.32 | - |
Other Long-Term Liabilities | - | - | - | - | 0.33 | 0.33 |
Total Liabilities | 14.87 | 12.73 | 12.08 | 11.04 | 18.84 | 13.96 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 125.26 | 125.2 | 121.16 | 114.3 | 104.58 | 40.07 |
Retained Earnings | -139.38 | -137.58 | -112.63 | -103.22 | -4.92 | -52.9 |
Treasury Stock | -0.01 | -0.01 | -0.01 | -0.01 | - | - |
Total Common Equity | -14.12 | -12.39 | 8.52 | 11.07 | 99.66 | -12.83 |
Shareholders' Equity | -14.12 | -12.39 | 8.52 | 11.07 | 99.66 | -12.83 |
Total Liabilities & Equity | 0.74 | 0.35 | 20.6 | 22.11 | 118.51 | 1.13 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.2 | - | - | 0.01 | 0.11 | 9.15 |
Net Cash (Debt) | -0.9 | 0.1 | 1.53 | 3.13 | 5.79 | -8.82 |
Net Cash Growth | - | -93.35% | -51.07% | -45.99% | - | - |
Net Cash Per Share | -0.12 | 0.02 | 1.38 | 32.09 | 0.25 | -3.65 |
Filing Date Shares Outstanding | 8.1 | 8.1 | 2.57 | 0.83 | 0.12 | 24.17 |
Total Common Shares Outstanding | 8.1 | 8.1 | 2.51 | 0.41 | 0.03 | 24.17 |
Working Capital | -14.12 | -12.39 | -9.52 | -6.84 | -1.83 | -12.81 |
Book Value Per Share | -1.74 | -1.53 | 3.40 | 27.33 | 3868.91 | -0.53 |
Tangible Book Value | -14.12 | -12.39 | -10.13 | -7.57 | -12.32 | -12.83 |
Tangible Book Value Per Share | -1.74 | -1.53 | -4.04 | -18.69 | -478.20 | -0.53 |
Machinery | - | - | - | 0.05 | 0.05 | 0.05 |